The Dual-Edged Sword: Risks and Benefits of JAK Inhibitors in Infections
Janus kinase inhibitors (JAKis) represent a relatively new class of immunomodulatory drugs with potent effects on various cytokine signalling pathways. They have revolutionized the treatment landscape for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis....
Saved in:
| Main Authors: | Anders Jarneborn, Pradeep Kumar Kopparapu, Tao Jin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/14/4/324 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of JAK Inhibitors in Lichen Planus: An Update
by: Dario Didona, et al.
Published: (2025-06-01) -
Successful treatment of recalcitrant follicular lichen planus (lichen planopilaris) with the topical JAK 1/2 inhibitor ruxolitinib
by: Tanja Fetter, et al.
Published: (2025-03-01) -
Exploratory study on the efficacy of topical pan-JAK inhibitor in ocular and skin GVHD in a sclerodermatous GVHD mouse model
by: Shinri Sato, et al.
Published: (2025-01-01) -
Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
by: Yachar Dawudi, et al.
Published: (2025-01-01) -
Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis
by: Qibei Teng, et al.
Published: (2025-07-01)